Chronic granulomatous disease (CGD) is a rare congenital immunodeficiency characterized by a defect in nicotinamide adenine dinucleotide phosphate oxidase required for phagocytosis. Hematopoietic stem cell (HSC) transplantation is currently the only curative treatment, but it is ladened with morbidities and mortality. Gene therapy is a promising treatment for CGD. However, if not properly designed, the gene therapy approach may not be successful. We engineered lentiviral vectors (LVs) carrying a universal promoter (EF1a) and two myeloid-specific promoters (miR223 and CD68) to drive the expression of green fluorescence protein (GFP) or CYBB, one of the key defective genes causing CGD. Tissue-specific LV expression was investigated in vitro and in a CGD mouse model. We compared GFP expression in both myeloid differentiated and undifferentiated HSCs. The CGD mice were transplanted with LV-modified mouse HSCs to investigate expression of CYBB and restoration of reactive oxygen species. The LV promoters were further compared under low and high-transgenic conditions to assess safety and therapeutic efficacy. A pneumonia disease model based on pathogenic Staphylococcus aureus challenge was established to assess the survival rate and body weight change. All three promoters demonstrated ectopic CYBB expression in vitro and in vivo. The EF1a promoter showed the highest expression of GFP or CYBB in transduced cells, including HSCs without cytotoxicity, whereas the LV-miR223 showed the highest transgene delivery efficiency with high myeloid specificity. Importantly, under low-transgenic condition, only the LV-EF1a-CYBB showed high antibacterial activity in vivo.
Get full access to this article
View all access options for this article.
References
1.
MartireB, RondelliR, SoresinaA, et al.Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: An Italian multicenter study. Clin Immunol, 2008; 126(2):155–164; doi: 10.1016/j.clim.2007.09.008
2.
WolachB, GavrieliR, de BoerM, et al.Chronic granulomatous disease: Clinical, functional, molecular, and genetic studies. The Israeli experience with 84 patients. Amer J Hematol, 2017; 92(1):28–36; doi: 10.1002/ajh.24573
3.
Van den BergJM, van KoppenE, AhlinA, et al.Chronic granulomatous disease: The European experience. PLoS One, 2009; 4(4):e5234; doi: 10.1371/journal.pone.0005234
4.
JonesLBKR, McGroganP, FloodTJ, et al.Special article: Chronic granulomatous disease in the United Kingdom and Ireland: A comprehensive national patient-based registry. Clin Exp Immunol, 2008; 152(2):211–218; doi: 10.1111/j.1365-2249.2008.03644.x
5.
MarcianoBE, FitzgeraldA, MannD, et al.Common severe infections in chronic granulomatous disease. Clin Infect Dis, 2015; 60; 1176–1183; doi: 10.1093/cid/ciu1154
6.
ContiF, Lugo-ReyesSO, Blancas GaliciaL, et al.Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol, 2016; 138(1):241–248 e3; doi: 10.1016/j.jaci.2015.11.041
7.
KimYM, SikHJ, ChoM, et al.Development of a lentiviral vector and an efficient infection method for gene therapy for p22phox-defective chronic granulomatous disease. J Korean Soc for Appl Biol Chem, 2012; 55(4):497–506; doi: 10.1007/s13765-012-2098-1
8.
ArnoldDE, HeimallJR. A review of chronic granulomatous disease. Adv Ther, 2017; 34(12):2543–2557; doi: 10.1007/s12325-017-0636-2
9.
GungorT, ChiesaR.Cellular therapies in chronic granulomatous disease. Front Pediatr, 2020; 8:327; doi: 10.3389/fped.2020.00327
10.
KangHJ, BartholomaeCC, ParuzynskiA, et al.Retroviral gene therapy for X-linked chronic granulomatous disease: Results from phase I/II trial. Mol Ther, 2011; 19(11):2092–2101; doi: 10.1038/mt.2011.166
11.
El KaresR, BarboucheMR, Elloumi-ZghalH, et al.Genetic and mutational heterogeneity of autosomal recessive chronic granulomatous disease in Tunisia. J Hum Genet, 2006; 51(10):887–895; doi: 10.1007/s10038-006-0039-8
12.
KannengiesserC, GerardB, El BennaJ, et al.Molecular epidemiology of chronic granulomatous disease in a series of 80 kindreds: Identification of 31 novel mutations. Hum Mutat, 2008; 29(9):E132–E149; doi: 10.1002/humu.20820
13.
DidiotMC, HallLM, ColesAH, et al.Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther, 2016; 24(10):1836–1847; doi: 10.1038/mt.2016.126
14.
WuZ, SunJ, ZhangT, et al.Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther, 2008; 16(2):280–289; doi: 10.1038/sj.mt.6300355
15.
SchneiderD, XiongY, WuD, et al.A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer, 2017; 5:42; doi: 10.1186/s40425-017-0246-1
16.
PrommersbergerS, HudecekM, NerreterT.Antibody-based CAR T cells produced by lentiviral transduction. Curr Protoc Immunol, 2020; 128(1):e93; doi: 10.1002/cpim.93
17.
JacksonZ, RoeA, SharmaA, et al.Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma. Front Immunol, 2020; 11:1941; doi: 10.3389/fimmu.2020.01941
18.
AgarwalS, WeidnerT, ThalheimerFB, et al.In vivo generated human CAR T cells eradicate tumor cells. Oncoimmunology, 2019; 8(12):e1671761; doi: 10.1080/2162402X.2019.1671761
19.
SchmidtsA, MarshLC, SrivastavaAA, et al.Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer, 2020; 8(2);e000990; doi: 10.1136/jitc-2020-000990
20.
MiloneMC, O'DohertyU. Clinical use of lentiviral vectors. Leukemia, 2018; 32(7):1529–1541; doi: 10.1038/s41375-018-0106-0
21.
WengJ, LaiP, QinL, et al.A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol, 2018; 11(1):25; doi: 10.1186/s13045-018-0572-x
22.
LevineBL, MiskinJ, WonnacottK, et al.Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev, 2017; 4:92–101; doi: 10.1016/j.omtm.2016.12.006
23.
Picanco-CastroV, MocoPD, MizukamiA, et al.Establishment of a simple and efficient platform for car-t cell generation and expansion: From lentiviral production to in vivo studies. Hematol Transfus Cell Ther, 2020; 42(2):150–158; doi: 10.1016/j.htct.2019.06.007
24.
VedvyasY, McCloskeyJE, YangY, et al.Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep, 2019; 9(1):10634; doi: 10.1038/s41598-019-46938-7
25.
FernandezL, FernandezA, VelaM, et al.GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS Prodigy. Front Immunol, 2019; 10:2361; doi: 10.3389/fimmu.2019.02361
26.
HernandezRJ, CalabriaA, SanvitoF, et al.Hematopoietic tumors in a mouse model of X-linked chronic granulomatous disease after lentiviral vector-mediated gene therapy. Mol Ther, 2021; 29(1):86–102; doi: 10.1016/j.ymthe.2020.09.030
27.
BraultJ, VigneB, MeunierM, et al.NOX4 is the main NADPH oxidase involved in the early stages of hematopoietic differentiation from human induced pluripotent stem cells. Free Radic Biol Med, 2020; 146:107–118; doi: 10.1016/j.freeradbiomed.2019.10.005
28.
ItoK, HiraoA, AraiF, et al.Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med, 2006; 12(4):446–451; doi: 10.1038/nm1388
JangYY, SharkisSJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood, 2007; 110(8):3056–3063; doi: 10.1182/blood-2007-05-087759
31.
AdaneB, YeH, StevensBM, et al.The hematopoietic oxidase NOX2 regulates self-renewal of leukemic stem cells. Cell Rep, 2019; 27(1):238–254.e6; doi: 10.1016/j.celrep.2019.03.009
32.
BigarellaCL, LiangR, GhaffariS. Stem cells and the impact of ROS signaling. Development, 2014; 141(22):4206–4218; doi: 10.1242/dev.107086
33.
SantilliG, AlmarzaE, BlundellMP, et al.Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther, 2011; 19(1):122–132; doi: 10.1038/mt.2010.226
34.
BrendelC, RotheM, KunkelH, et al.Non-clinical efficacy and safety studies on G1XCGD, a lentiviral vector for ex vivo gene therapy of X-linked chronic granulomatous disease. Hum Gene Ther Clin Dev, 2018; 29(2):69–79; doi: 10.1089/humc.2017.245
35.
RoeslerJ, BrennerS, MalechHL, et al.Third-generation, self-inactivating gp91phox lentivector corrects the oxidase defect in NOD/SCID mouse–repopulating peripheral blood–mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Gene Ther, 2002; 100(13):4381–4390; doi: 10.1182/blood-2001-12-0165
36.
BardeI, LaurentiE, TronoD, et al.Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Ther, 2011; 1(11):1–10; doi: 10.1038/gt.2011.65
37.
ChiriacoM, FarinelliG, CapoV. et al. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Am Soc Gene Cell Ther, 2014; 22(8):1472–1483; doi: 10.1038/mt.2014.87
38.
HaenselerW, KuzmenkoE, SilerU, et al.Lentiviral gene therapy vector with UCOE stably restores function in iPSC-derived neutrophils of a CDG patient. Matters (Zur), 2018; 2018:1–11; doi: 10.19185/matters.201805000005
39.
SteinS, OttMG, KinnerA, et al.Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med, 2010; 16(2):198–204; doi: 10.1038/nm.2088
40.
BrendelC, HanselerW, Chen-WichmannL, et al.Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. Hum Gene Ther Methods, 2013; 24(3):151–159; doi: 10.1089/hgtb.2012.157
41.
ToscanoMG, RomeroZ, MunozP, et al.Physiological and tissue-specific vectors for treatment of inherited diseases. Gene Ther, 2011; 18(2):117–127; doi: 10.1038/gt.2010.138
42.
KustikovaOS, BartelsS, LiZ, et al.Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther, 2009; 17(9):1537–1547; doi: 10.1038/mt.2009.134
43.
ZychlinskiD, MeyerJ, GrassmanE, et al.Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther, 2008; 16(4):718–725; doi: 10.1038/mt.2008.5
44.
HeydemannA, WarmingS, ClendeninC, et al.A minimal c-fes cassette directs myeloid-specific expression in transgenic mice. Blood, 2000; 96(9):3040–3048; doi: 10.1182/blood.V96.9.3040
45.
MontiniE, CesanaD, RanzaniM, et al.The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest, 2009; 119(4):964–975; doi: 10.1172/JCI37630
46.
CesanaD, SgualdinoJ, RudilossoL, et al.Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest, 2012; 122(5):1667–1676; doi: 10.1172/JCI62189
47.
KohnDB, BoothC, SantilliG, et al.Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med, 2020; 26(2):200–206; doi: 10.1038/s41591-019-0735-5
48.
ChangL-J, UrlacherV, IwakumaT, et al.Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther, 1999; 6:715–728; doi: 10.1038/sj.gt.3300895
49.
IwakumaT, CuiY, ChangL-J. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology, 1999; 261(1):120–132; doi: 10.1006/viro.1999.9850
50.
ChenX, HeJ, ChangL-J. Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology, 2004; 1:37; doi: 10.1186/1742-4690-1-37
51.
ChangL-J.Lentiviral vector transduction of dendritic cells for novel vaccine strategies. Methods Mol Biol, 2010; 614:161–171; doi: 10.1007/978-1-60761-533-0_11
52.
GongJ, ChungTH, ZhengJ, et al.Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A. J Biol Chem, 2021; 297(6):101397; doi: 10.1016/j.jbc.2021.101397
53.
GomezMI, LeeA, PittA, et al.Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat Med, 2004; 10(8):842–848; doi: 10.1038/nm1079
CoxJE, CamposS, RamosCA, et al.Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant, 2014; 49(2):219–222; doi: 10.1038/bmt.2013.149
56.
FarinelliG, HernandezRJ, RossiA, et al.Lentiviral vector gene therapy protects X-CGD mice from acute Staphylococcus aureus pneumonia and inflammatory response. Mol Ther, 2016; 24(10):1873–1880; doi: 10.1038/mt.2016.150
57.
MarcianoBE, ZerbeCS, DaubJ, et al.X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability. J Allergy Clin Immunol, 2018; 141(1):365–371; doi: 10.1007/s12325-017-0636-2
MalechHL, MaplesPB, Whiting-TheobaldN, et al.Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A, 1997; 94:12133–12138; doi: 10.1073/pnas.94.22.12133
60.
JohnnidisJB, HarrisMH, KirakO, et al.Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature, 2008; 451(7182):1125–1129; doi: 10.1038/nature06607
61.
FukaoT, FukudaY, EnomotoY, et al.An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell, 2007; 129(3):617–631; doi: 10.1016/j.cell.2007.02.048
62.
LandgrafP, RusuM, AravinA, et al.A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 2007; 129(7):1401–1414; doi: 10.1016/j.cell.2007.04.040
63.
DoeringCB, DenningG, SrivastavaA, et al.Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A. Hum Gene Ther, 2018; 29(10):1183–1201; doi: 10.1089/hum.2018.137
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
